Aclaris Therapeutics to Participate in Two February Healthcare Conferences
Aclaris Therapeutics (NASDAQ: ACRS) will participate in two healthcare conferences in February 2026 with senior management presentations and webcasts available.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ: ACRS) will participate in two healthcare conferences in February 2026 with senior management presentations and webcasts available.
On Feb 12, 2026 at 2:30 PM EST CEO Dr. Neal Walker will join a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit. On Feb 26, 2026 at 8:40 AM EST President COO Hugh Davis will present at Oppenheimer 36th Annual Healthcare Life Sciences Conference. Webcasts will be available on the company website for at least 30 days.
Details
News Market Reaction – ACRS
On Feb 4, the day this news came out, ACRS closed 2.02% above the previous close.
Data tracked by StockTitan Argus for the Feb 4 session.
Key Figures
- Number of conferences
- 2 conferences
- February 2026 healthcare conferences
- First conference date
- February 12, 2026
- Guggenheim Emerging Outlook: Biotech Summit 2026
- First conference time
- 2:30 PM EST
- Guggenheim Summit fireside chat
- Second conference date
- February 26, 2026
- Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Second conference time
- 8:40 AM EST
- Oppenheimer conference corporate presentation
- Webcast availability
- 30 days
- Archived webcasts on Aclaris website
- Current share price
- $3.47
- Price before conference participation news
- Price vs 52-week high
- -29.04%
- Distance from 52-week high of $4.89
Historical Context
-
ATI-2138 showed rapid, sustained hair regrowth in murine alopecia model.
-
Initiated Phase 1b proof-of-concept trial in atopic dermatitis for ATI-052.
-
Positive interim Phase 1a ATI-052 results with favorable safety and robust PD.
-
Added to Nasdaq Biotechnology Index effective close on December 19, 2025.
-
Announced participation in Piper Sandler healthcare conference with webcast access.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in February 2026.
- On Thursday February 12, 2026, at 2:30 PM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY.
- On Thursday February 26, 2026, at 8:40 AM EST, Aclaris’ President and Chief Operating Officer Hugh Davis, Ph.D. will provide a corporate presentation during the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference.
A live and archived webcast of both events will be accessible on the Events page of https://www.aclaristx.com/. The webcasts will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.